Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Taiwan study tracks Real-World safety of obesity drug saxenda

NCT ID NCT06283641

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at the safety and effectiveness of the weight-loss drug Saxenda (liraglutide) in 300 obese adults and teenagers in Taiwan. Participants took the drug as part of their normal care for about 26 weeks. The main goal was to track any side effects and see how well the drug worked in everyday practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Liraglutide (Saxenda)
What this could lead to
If results are positive, this could confirm that Saxenda is safe and effective for weight management in Taiwanese patients in real-world settings.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only lasted 26 weeks and focused on safety, not long-term weight loss.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

300 people

The number who actually took part.

Started

Apr 2024

Finished

Jan 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants are patients with obesity treated with Saxenda® for weight management in routine clinical practice in Taiwan

Ages

12 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or Female of Taiwanese patients, age above or equal to 12 years who are under Saxenda® treatment or are scheduled to treat with Saxenda® according to approved label in Taiwan based on the clinical judgment of their treating physician. 2. Patients should have baseline (pre-dosing) values, including body height, weight and initial dosage of Saxenda® . 3. The decision to initiate treatment or to have started with commercially available Saxenda® has been made by the patient/Legally Acceptable Representative (LAR) and the physician independently from the decision to join this study. 4. Informed consent obtained before collection of clinical data for this study. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. Exclusion Criteria: 1. Known or suspected hypersensitivity to Saxenda® , the active substance or any of the excipients 2. Previous participation in this study. Participation is defined as having given informed consent in this study. 3. Treatment with any investigational drug within 30 days prior to initiation of Saxenda® treatment. 4. Female patient who is pregnant, breast-feeding, or intends to become pregnant. 5. Patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). 6. Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity

Contacts and locations

Locations

  • Chang Gung Memorial Hospital, Linkou

    Taoyuan, 333, Taiwan

  • Changhua Christian Hospital_Metabolic Dept.

    Changhua, 500, Taiwan

  • China Medical University Hospital

    Taichung, 404, Taiwan

  • Ditmanson Medical Foundation Chia-Yi Christian Hospital

    Chiayi City, 600, Taiwan

  • Genesis Clinic

    Taipei, 104, Taiwan

  • HsinChu MacKay Memorial Hospital

    Hsinchu, 300, Taiwan

  • HsinChu Municipal MacKay Children's Hospital

    Hsinchu, 300, Taiwan

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, 807, Taiwan

  • Kuang Tien General Hospital

    Taichung, 433, Taiwan

  • National Taiwan University Hospital

    Taipei, 100229, Taiwan

  • National Taiwan University Hospital_main

    Taipei, 100, Taiwan

  • TZ Clinic

    Pingtung County, 900, Taiwan

  • Taipei Medical University Hospital

    Taipei, 110, Taiwan

  • Ton-Yen General Hospital

    Hsinchu County, 302, Taiwan

  • Tungs Taichung MetroHarbor Hospital

    Taichung, 435, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.